Can a new drug slow lung scarring in IPF?
NCT ID NCT07719023
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether an experimental drug called AK3280 can slow the decline in lung function for people with idiopathic pulmonary fibrosis (IPF), a condition that causes progressive lung scarring. About 263 adults aged 40 and older with IPF will receive either AK3280, a placebo, or the active control pirfenidone. The main goal is to see how lung function, measured by forced vital capacity (FVC), changes over 52 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called AK3280
- What this could lead to
- If successful, AK3280 could offer a new treatment option to slow lung function decline in people with idiopathic pulmonary fibrosis.
- What could go wrong
- This is an early-phase trial, and the drug may not prove more effective than existing treatments or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Blood tests could unlock early clues for three major lung diseases
- AI could uncover hidden lung disease in routine chest X-Rays
- Inhaled drug could offer new hope for lung scarring disease
- New hope for lung scarring: AZD8965 enters Mid-Stage trial
- Smart cap aims to boost medication adherence in lung disease patients